Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod

Key Points

• The study aims to evaluate the effectiveness of efgartigimod in treating generalized myasthenia gravis and its impact on serum IgG levels.
• Administration of efgartigimod alongside immunosuppressants.
• Monitoring clinical symptoms and serum IgG levels in participants.
• Follow-up observations to assess long-term control of the disease.
• Significant improvement in clinical symptoms was observed in patients.
• Serum IgG levels were notably reduced with efgartigimod treatment.
• Long-term disease control is enhanced when used in combination with immunosuppressants.